Pricing
  1. US-listed companies
  2. SELLAS Life Sciences Group, Inc.
  3. Financials
  4. Total cash & short-term investments

SELLAS Life Sciences Group, Inc. (SLS)

Market cap
$552.77M
P/E ratio
SummaryFinancials
Period EndTotal cash & short-term investments (Million USD)YoY (%)
Dec 31, 202414+431.79%
Dec 31, 20233-84.73%
Dec 31, 202217-19.72%
Dec 31, 202121-39.40%
Dec 31, 202035+379.90%
Dec 31, 20197+35.33%
Dec 31, 20185+135.06%
Dec 31, 20172-87.18%
Dec 31, 201618-39.18%
Dec 31, 201530+25.71%
Dec 31, 201424-50.51%
Dec 31, 201348+45.66%
Dec 31, 201233+186.95%
Dec 31, 201111

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat